bjd12626-sup-0001-TableS1-S3-FigS1.docWord document113K

Table S1. Mean (standard deviation) changes from baseline in Investigator's Global Assessment (IGA) score and symptom scores at weeks 8 and 12, showing statistical significance for comparisons between liarozole and placebo groups (intent-to-treat population).

 Table S2. Liarozole predose and near-peak plasma concentrations.

 Table S3. Summary of adverse events (safety population).

 Fig. S1. Change in mean Dermatology Life Quality Index (DLQI) over time (intent-to-treat population; last observation carried forward).

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.